34 results on '"Borel C"'
Search Results
2. 896P Long-responders to ICI in R/M-HNSCC: A retrospective multicentric French cohort
3. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
4. 935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
5. 923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
6. 758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
7. 752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
8. 925P Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
9. 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
10. 930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
11. 676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
12. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients
13. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma
14. Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study
15. Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer
16. Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
17. Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study
18. Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial
19. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort
20. TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
21. First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial
22. Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial
23. 1150P - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
24. 549P - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study
25. Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR
26. 1488P - Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial
27. 1065P - TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
28. 1048O - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort
29. 877P - First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial
30. 557P - Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial
31. Genomic Profile of Early Stage Node-Negative Luminal Breast Cancer Associated with Short Disease-Specific Survival
32. 986P - Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR
33. 285P - Genomic Profile of Early Stage Node-Negative Luminal Breast Cancer Associated with Short Disease-Specific Survival
34. Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.